Table I.
Results from the ex vivo study.
| DAB concentration | APCr ratio | p | p | p | |
|---|---|---|---|---|---|
| O | 0 ng/mL | 3.69±0.41 | |||
| A | <100 ng/mL | 5.38±0.66 | O vs A p<0.01 | ||
| B | 100–200 ng/mL | 6.88±0.88 | O vs B p<0.005 | A vs B p<0.05 | |
| C | >200 ng/mL | 7.77±1.02 | O vs C p<0.001 | A vs C p<0.01 | B vs C P<0.05 |
| DAB concentration | APCr ratio | ||||
| O1 | 0 ng/mL | 1.34±0.08 | |||
| A1 | <100 ng/mL | 1.79±0.11 | O1 vs A1 p<0.05 | ||
| B1 | 100–200 ng/mL | 2.23±0.14 | O1 vs B1 p<0.01 | A1 vs B1 p<0.05 | - |
| C1 | >200 ng/mL | 2.74±0.83 | O1 vs C1 p<0.001 | A1 vs C1 p<0.01 | B1 vs C1 p<0.05 |
APCr: activated protein C resistance; DAB: dabigatran etexilate; FV wild-type homozygous subjects: groups O, A, B and C. FV Leiden heterozygous patients: groups O1, A1, B1 and C1.